Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial The Lancet 381, 805-816, 2012 | 2425* | 2012 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer JJCHSHNCCGT R. Hitt, J. J. Grau, A. López-Pousa, A. Berrocal, C. García ... Annals of Oncology 25 (1), 216-225, 2013 | 358* | 2013 |
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study INCESGINCEU Ruth Pettengell,Matthias Schwenkglenks, Robert Leonard, André ... Supportive Care in Cancer 16 (11), 1299-1309, 2008 | 151 | 2008 |
Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study MSINCESGINCEU Ruth Pettengell, Andre´ Bosly, Thomas D. Szucs, Christian ... British Journal of Haematology 144 (5), 677–685, 2008 | 116* | 2008 |
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Y Escobar, G Cajaraville, JA Virizuela, R Álvarez, A Muñoz, O Olariaga, ... Supportive Care in Cancer 23, 2833-2840, 2015 | 93 | 2015 |
Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples I Cruz, J Ciudad, JJ Cruz, M Ramos, A Gómez-Alonso, JC Adansa, ... American journal of clinical pathology 123 (1), 66-74, 2005 | 92 | 2005 |
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study RL Matthias Schwenkglenks, Ruth Pettengell, Christian Jackisch, Robert ... Supportive Care in Cancer 19 (4), 483–490, 2010 | 75* | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment J Martinez-Trufero, D Isla, JC Adansa, A Irigoyen, R Hitt, I Gil-Arnaiz, ... British journal of cancer 102 (12), 1687-1691, 2010 | 65 | 2010 |
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location R Seijas-Tamayo, J Fernández-Mateos, JC Adansa Klain, R Mesía, ... Clinical and Translational Oncology 18, 1114-1122, 2016 | 32 | 2016 |
Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma J Fernández-Mateos, R Seijas-Tamayo, JCA Klain, MP Borgoñón, ... Scientific reports 7 (1), 6887, 2017 | 26 | 2017 |
Genetic susceptibility in head and neck squamous cell carcinoma in a Spanish population J Fernández-Mateos, R Seijas-Tamayo, JC Adansa Klain, ... Cancers 11 (4), 493, 2019 | 23 | 2019 |
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a … J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, ... Oral oncology 63, 38-43, 2016 | 23 | 2016 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study E del Barco Morillo, R Mesía, JCA Klain, SV Fernández, J Martínez-Galán, ... Oral Oncology 62, 54-59, 2016 | 17 | 2016 |
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial J Fernández-Mateos, J Perez-Garcia, R Seijas-Tamayo, R Mesía, ... Scientific RepoRtS 10 (1), 16634, 2020 | 14 | 2020 |
Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous … J Martinez-Trufero, D Isla, JC Adansa, A Irigoyen, R Hitt, J Lambea, ... Journal of Clinical Oncology 27 (15_suppl), 6047-6047, 2009 | 10 | 2009 |
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer … J Martínez-Trufero, A Lozano Borbalas, I Pajares Bernad, ... Clinical and Translational Oncology 23, 1666-1677, 2021 | 7 | 2021 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study EDB Morillo, R Mesía, JCA Klain, SV Fernández, J Martínez-Galán, ... Oral oncology 62, 54-59, 2016 | 5 | 2016 |
Spanish Head and Neck Cancer Cooperative Group (TTCC). Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally … J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, ... Oral Oncol 63, 38-43, 2016 | 5 | 2016 |
Induction Chemotherapy (Ict) with Docetaxel/Cisplatin/5-Fluorouracil (T/P/F) Followed By Chemoradiotherapy with Cisplatin (Crtp) Vs Bioradiotherapy with Cetuximab (Rtcx) for … R Hitt, R Mesia, JJ Grau, J Rubió, J Martínez-Trufero, EDB Morillo, ... Annals of Oncology 25, iv355, 2014 | 2 | 2014 |
2802 Phase II study of first-line paclitaxel (PTX) with panitumumab (P) in patients with metastatic or recurrent head and neck cancer: TTCC-2009-03 study EDB Morillo, R Mesia, JCA Klain, SV Fernández, JM Galan, ... European Journal of Cancer 3 (51), S558, 2015 | 1 | 2015 |